HETEROCYCLIC COMPOUNDS AND USES AS ANTICANCER AGENTS
Novel compounds having a fused bicyclic heteroaromatic ring system substituted with a thiazole ring are disclosed. The compounds inhibit growth of a variety of types of cancer cells, and are thus useful for treating cancer. Efficacy of these compounds is demonstrated with a system for monitoring cell growth/migration, which shows they are potent inhibitors of growth and/or migration of cancer cells. In addition, compounds of the invention were shown to stop growth of tumors in vivo, and to reduce the size of tumors in vivo. Compositions comprising these compounds, and methods to use these compounds and compositions for treatment of cancers, are disclosed.
1 . A compound of formula (I) or Formula (II):
wherein Z is selected but not limited from the following substituted phenyl or heterocyclic rings:
or a pharmaceutically acceptable salt thereof.
2 . The compound of claim 1 , which is a compound of the formula (I).
3 . The compound of claim 1 , which is a compound of the formula (II).
4 . A compound of the formula (I) selected from
5 . A compound of the formula (II) selected from
6 . A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient or carrier.
7 . The pharmaceutical composition of claim 6 , which further comprises an additional active agent.
8 . The pharmaceutical composition of claim 7 , wherein the additional active agent is a large molecule or a small molecule.
9 . The pharmaceutical composition of claim 8 , wherein the large molecule is hematopoietic growth factors, cytokines, and monoclonal or polyclonal antibodies.
10 . The pharmaceutical composition of claim 8 , wherein the small molecule is anti-cancer agents, antibiotics, immunosuppressive agents or steroids.
11 . A method of treating, preventing or managing cancer comprising administering to a subject in need of such treatment an effective amount of a compound of claim 1 .
12 . The method of claim 11 , wherein the subject is a human.
13 . The method of claim 11 , wherein the cancer is sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head cancer, neck cancer, or pancreatic cancer.
14 . A method of treating, preventing or managing cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition of claim 6 .
15 . The method of claim of claim 14 , wherein the subject is a human.
16 . The method of claim 14 , wherein the cancer is sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head cancer, neck cancer, or pancreatic cancer.
17 . A method of treating, preventing or managing cancer comprising administering to a subject in need of such treatment an effective amount of a pharmaceutical composition of claim 7 .
18 . The method of claim of claim 17 , wherein the subject is a human.
19 . The method of claim 17 , wherein the cancer is sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head cancer, neck cancer, or pancreatic cancer.
20 . A compound of claim 1 for use to treat cancer.
21 . The compound of claim 20 , wherein the cancer is sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head cancer, neck cancer, or pancreatic cancer.
22 . Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of cancer.
23 . The compound of claim 22 , wherein the cancer is sarcoma, epidermoid cancer, fibrosarcoma, cervical cancer, gastric carcinoma, skin cancer, leukemia, lymphoma, lung cancer, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, prostate cancer, breast cancer, liver cancer, head cancer, neck cancer, or pancreatic cancer.